<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Antibodies (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Antibodies (Basel)</journal-id><journal-id journal-id-type="publisher-id">antibodies</journal-id><journal-title-group><journal-title>Antibodies</journal-title></journal-title-group><issn pub-type="epub">2073-4468</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7345743</article-id><article-id pub-id-type="doi">10.3390/antib9020021</article-id><article-id pub-id-type="publisher-id">antibodies-09-00021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Construction of Antibody Phage Libraries and Their Application in Veterinary Immunovirology</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bashir</surname><given-names>Shahbaz</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2396-354X</contrib-id><name><surname>Paeshuyse</surname><given-names>Jan</given-names></name><xref rid="c1-antibodies-09-00021" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-antibodies-09-00021">Department of Biosystems, Division of Animal and Human Health Engineering, Laboratory of Host Pathogen Interaction in Livestock, KU Leuven University, 3000 Leuven, Belgium; <email>shahbaz.bashir@kuleuven.be</email></aff><author-notes><corresp id="c1-antibodies-09-00021"><label>*</label>Correspondence: <email>jan.paeshuyse@kuleuven.be</email>; Tel.: +32-16-37-4654</corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>6</month><year>2020</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2020</year></pub-date><volume>9</volume><issue>2</issue><elocation-id>21</elocation-id><history><date date-type="received"><day>23</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>4</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 by the authors.</copyright-statement><copyright-year>2020</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Antibody phage display (APD) technology has revolutionized the field of immunovirology with its application in viral disease diagnostics and antiviral therapy. This robust and versatile technology allows the expression of an antibody fused to a phage coat protein on the surface of a filamentous phage. The DNA sequence coding for the antibody is packaged within the phage, linking the phenotype to genotype. Antibody phage display inherits the ability to rapidly generate and modify or improve high-affinity monoclonal antibodies, rendering it indispensable in immunology. In the last two decades, phage-display-derived antibodies have been extensively used in human medicine as diagnostic and therapeutic modalities. Recently, they are also gaining significant ground in veterinary medicine. Even though these advancements are mainly biased towards economically important animals such as chicken, cattle, and pigs, they are laying the foundation of fulfilling the unmet needs of veterinary medicine as antibody-based biologics in viral diagnostics, therapeutics, and immunoprophylaxis. This review provides a brief overview of the construction of antibody phage libraries and their application in diagnosis, prevention, and control of infectious viral diseases in veterinary medicine in detail.</p></abstract><kwd-group><kwd>phage display</kwd><kwd>immunovirology</kwd><kwd>monoclonal antibody</kwd><kwd>veterinary medicine</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-antibodies-09-00021"><title>1. Introduction</title><p>Phage display has emerged as a very powerful, robust, and effective molecular technique to generate vast libraries containing millions or even billions of different peptides or proteins. It includes batch cloning of DNA encoding for millions of variants of certain ligands (e.g., peptides and proteins or fragments thereof) into the phage genome as part of one of the phage coat proteins (p &#x02162;, p &#x02165;, or p &#x02167;). Exposition of proteins or polypeptides on the surface of phage is achieved by fusion of the coding sequence of one of the coat proteins to the gene of interest, which helps in isolating the specific binding ligands by a series of recursive cycles of selection on antigen or ligand with each cycle comprising of binding, washing, elution, and amplification. Generally, proteins are displayed on phage particle tethered to either minor coat proteins like p &#x02162; or the major coat proteins like p &#x02167;, yet retaining its structure/function. Based on the direct linkage between phenotype and genotype, phage display technology (PDT) provides an expedient approach to study the genetics and functionality of the interacting proteins and peptides [<xref rid="B1-antibodies-09-00021" ref-type="bibr">1</xref>]. Following the initial demonstration of peptide display, antibodies were the first functional proteins to be successfully displayed on the phage surface. In a humoral immune response, antibodies serve as antigen-targeting effector molecules. Their unique tetrameric structure consists of two identical light and two identical heavy chains joined together by disulfide bridges and non-covalent interactions. Each chain is comprised of a series of discreet repeats, forming a compactly folded regions of proteins called &#x0201c;antibody domains&#x0201d; (<xref ref-type="fig" rid="antibodies-09-00021-f001">Figure 1</xref>). Antibodies are modular protein defense systems possessing a paratope (variable domain), an antigen-binding site located at the upper tips of the &#x0201c;Y&#x0201d;-shaped structure. These paratopes identify the specific epitope displayed by the antigen and tag the microbe as well as the infected cell to be recognized by the immune system for neutralization. Therefore, these variable domains serve as paradigmatic proteinaceous scaffolds to be expressed on the phage surface for the isolation of novel binders against a myriad of antigens. Phage display of combinatorial antibody libraries is an efficient technique by which monoclonal antibodies (mAbs) of a desired specificity can be selected without the use of conventional hybridoma technology [<xref rid="B2-antibodies-09-00021" ref-type="bibr">2</xref>]. Their unique maturation process helps them to evolve to be highly specific to viral antigens, opening new horizons in viral disease diagnosis and therapeutics. In the last few decades, the prime focus of the developed recombinant antibodies was targeted towards human medicine, but now the shift in trends towards veterinary medicine seems promising. In spite of skewed research trends towards economically important livestock species such as cows, poultry, sheep, goats, and pigs, there is a vast field of veterinary medicine waiting for the application of mAbs developed through antibody phage display. Furthermore, efficient techniques have been established and optimized to design, build, and manipulate the vast antibody fragment-based libraries in order to derive the antibodies of desired characteristics and affinity. Here, we encompass the progress in this rapidly growing field and discuss its application in finding new diagnostics and therapeutic viral targets in veterinary medicine in association with other complementary technologies. </p></sec><sec id="sec2-antibodies-09-00021"><title>2. Antibody Phage Display Library Construction and Biopanning</title><p>An antibody phage library is the collection of antibody variable domains displaying phages with library size 10<sup>6</sup>&#x02013;10<sup>11</sup>, depending on the library type, fused to their coat proteins as a result of antibody-variable fragment (gene) cloning. Here, we shall briefly describe the construction of a phagemid-based antibody (scFv and Fab) phage display library from immunized or na&#x000ef;ve sources. The basic methodology to build APD library from the V-gene repertoire (<xref ref-type="fig" rid="antibodies-09-00021-f002">Figure 2</xref>) is almost the same, starting with the extraction of mRNA from B-cells isolated from blood, spleen, tonsils, and tumor tissue samples. Using oligo (dt) primers or random primers, cDNA is synthesized from mRNA through reverse transcription-polymerase chain reaction. Defined PCR primer sets, designed on the basis of species consensus sequence and anneal to the conserved region of V-gene families or constant domain, are used to amplify the heavy chain and light chain corresponding region (V<sub>H</sub> and V<sub>L</sub>; V<sub>H</sub>, C<sub>H</sub>, V<sub>L</sub> and C<sub>L</sub>, respectively) genes within a given immunoglobulin repertoire from cDNA pools, thus revealing the all antibody specificities in a particular individual [<xref rid="B4-antibodies-09-00021" ref-type="bibr">4</xref>]. The PCR-amplified V<sub>H</sub> and V<sub>L</sub> and V<sub>H</sub>-C<sub>H</sub> and V<sub>L</sub>-C<sub>L</sub> gene fragments are ligated in a suitable phagemid for single-chain variable fragment (scFv) and Fab library generation, respectively. In the case of synthetic antibody phage libraries, the initial few steps are not needed, and library diversity is increased through the precise introduction of degenerate DNA into CDR encoding regions, thus rivaling or exceeding than that of natural immune repertoire [<xref rid="B5-antibodies-09-00021" ref-type="bibr">5</xref>]. </p><p>The engineered phagemids are transformed into suitable bacteria (e.g., XL1-Blue, TG1, and ER2537), providing a suitable environment for recombination of antibody fragments [<xref rid="B6-antibodies-09-00021" ref-type="bibr">6</xref>]. For rescuing the recombinant phagemid harboring the gene of inserts like Fab or scFv, the transformed bacteria are infected with helper phages like VCSM13 or M13KO7. These phages belong to the M13 class of bacteriophages and are well-adapted for the exposition of antibody-variable scaffolds (<xref ref-type="fig" rid="antibodies-09-00021-f003">Figure 3</xref>). This results in a library of phages, where each phage is expressing a unique antibody fragment on its surface as a phenotype while possessing the vector with specific nucleotide sequences within as respective genotypes [<xref rid="B7-antibodies-09-00021" ref-type="bibr">7</xref>,<xref rid="B8-antibodies-09-00021" ref-type="bibr">8</xref>].</p><p>Now, this antibody phage library is ready to pan against the antigen of choice. By using this methodology, antibody phage libraries of different antibody formats have been successfully constructed, such as Fab (antigen-binding fragment), Fv (variable fragment), scFv (single-chain variable fragment), and its modifications [<xref rid="B9-antibodies-09-00021" ref-type="bibr">9</xref>,<xref rid="B10-antibodies-09-00021" ref-type="bibr">10</xref>] diabodies, and other oligomers [<xref rid="B11-antibodies-09-00021" ref-type="bibr">11</xref>,<xref rid="B12-antibodies-09-00021" ref-type="bibr">12</xref>]. The science of selection of high-affinity clones is as important as the generation of large, diverse, and more rational antibody libraries. Antigen-specific clones, phages displaying antibody fragments, are screened and enriched from antibody libraries through an iterative process based on interaction affinity, avidity, and binding kinetics between the expressed antibody fragment and the antigen of interest called biopanning. It includes recursive cycles of pooling of antibody displaying phages, incubation with antigen, removal of unbound phages (washing), elution of bound phages, re-amplification in F<sup>+</sup>
<italic>E. coli</italic>, and re-selection (<xref ref-type="fig" rid="antibodies-09-00021-f004">Figure 4</xref>) [<xref rid="B13-antibodies-09-00021" ref-type="bibr">13</xref>]. It represents as a high throughput antibody library screening strategy allowing screening of a library with up to 10<sup>11</sup> variants and also isolation and characterization of high-affinity binders with a frequency as low as 1 in 10<sup>6</sup> by mimicking the same process by which immune system selects antibodies against a specific antigen through affinity maturation. A strong combination of interactive affinity selection and biological amplification controls the overall strength of the biopanning procedure. There are various types of biopanning strategies in practice, but selecting only one is very much dependent on the nature, functionality, and native environment of the antigen. The choice of screening method can directly influence the antibody phage output number and diversity among selected clones. Therefore, it should be adapted to fit the respective class of antigen [<xref rid="B14-antibodies-09-00021" ref-type="bibr">14</xref>]. Biopanning strategies against pure or soluble antigens are well established and have been performed against pure or non-membranous protein antigens by immobilizing it to a solid support through adsorption, such as immunotubes [<xref rid="B15-antibodies-09-00021" ref-type="bibr">15</xref>,<xref rid="B16-antibodies-09-00021" ref-type="bibr">16</xref>], microtiter plates, and BIAcore sensor chips [<xref rid="B17-antibodies-09-00021" ref-type="bibr">17</xref>,<xref rid="B18-antibodies-09-00021" ref-type="bibr">18</xref>,<xref rid="B19-antibodies-09-00021" ref-type="bibr">19</xref>,<xref rid="B20-antibodies-09-00021" ref-type="bibr">20</xref>]. On the other hand, membrane-associated proteins, possessing hydrophobic domains, account for 20%&#x02013;30% of all protein in living entities, thus presenting themselves as desirable targets for APD in order to obtain novel mAbs for research, diagnostic, and therapeutic purposes [<xref rid="B21-antibodies-09-00021" ref-type="bibr">21</xref>]. Direct panning on whole cells, displaying the complex target antigen on their surface, alongside existing ligand guided &#x0201c;pathfinder&#x0201d; biopanning strategy, has proven to be a reasonable modality in selecting high-affinity antibody clones against membrane proteins [<xref rid="B22-antibodies-09-00021" ref-type="bibr">22</xref>,<xref rid="B23-antibodies-09-00021" ref-type="bibr">23</xref>]. Alternatively, detergent micelles and nanodiscs have evolved as an interesting substitute for membrane protein expression for the isolation of novel antibody binders [<xref rid="B24-antibodies-09-00021" ref-type="bibr">24</xref>,<xref rid="B25-antibodies-09-00021" ref-type="bibr">25</xref>,<xref rid="B26-antibodies-09-00021" ref-type="bibr">26</xref>,<xref rid="B27-antibodies-09-00021" ref-type="bibr">27</xref>]. In recent times, virus-like particles (VLPs) have emerged as an interesting platform allowing multivalent display of membrane proteins and are yet to be explored for the screening of novel binders against membrane target proteins [<xref rid="B28-antibodies-09-00021" ref-type="bibr">28</xref>]. In spite of this progress in membrane protein expression for the pursuit of new antiviral targets, mechanistic linkages between a protein&#x02019;s conformational transitions and its function pose a significant challenge.</p><sec><title>Quality Assessment of an Antibody Library</title><p>The performance of an antibody library is directly linked to its quality. The salient features governing the library quality control include (a) the number of clones with phagemids harboring the insert, i.e., scFv or Fab, (b) the number of clones expressing phages carrying inserts, and (c) the number of clones capable of soluble expression of inserts. The key parameter of an antibody library&#x02019;s quality is its complexity, also called diversity. It is an estimate of distinct elements in that collection. It directly reflects the probability of screening an antibody clone from the library against a given antigen, of sufficiently higher affinity. Theoretically, the probability of finding a functional antibody against a given antigen is higher in large complex or more diverse libraries than in a less complex or diverse library. It is approximated by the transformation efficiency of the bacteria used to amplify the library. Despite the simplicity and significance of this concept, the accurate and reliable quantification of this prime feature was not possible and is still lacking [<xref rid="B29-antibodies-09-00021" ref-type="bibr">29</xref>,<xref rid="B30-antibodies-09-00021" ref-type="bibr">30</xref>]. PCR screening of individual clones to determine the presence of insert, dot plot analysis to detect both antibody fragment displaying phages, and soluble antibody fragment synthesized by the screened clones, and further characterization of the few hundred positive clones through DNA fingerprinting and sequencing are still considered standard practices [<xref rid="B31-antibodies-09-00021" ref-type="bibr">31</xref>,<xref rid="B32-antibodies-09-00021" ref-type="bibr">32</xref>]. Recently, a reseach group used a PCR-free next-generation sequencing (NGS) approach coupled with new bioinformatic tools for the reliable and accurate estimation of the diversity of a library [<xref rid="B33-antibodies-09-00021" ref-type="bibr">33</xref>]. However, further optimization and advancement in NGS is required to fully exploit the potential of this incredible technology in tackling the antibody library diversity quality assessment.</p></sec></sec><sec id="sec3-antibodies-09-00021"><title>3. Application of APD in Veterinary Immunovirology</title><p>Immunovirology, also called viral immunology, encompasses the evolution of the immune system as a result of its interaction with viruses. In 1996, Zinkernagel published an article titled &#x0201c;Immunology taught by viruses&#x0201d;, explaining this incredible interaction between viruses and the immune system [<xref rid="B34-antibodies-09-00021" ref-type="bibr">34</xref>]. Despite the fact that previously, human medicine was the focal point of recombinant antibodies development through antibody phage display, recent advancements in veterinary medicine are promising. In the field of veterinary medicine, the impact of viral infections on animal welfare and health cannot be neglected. Major strides have been taken in veterinary diagnostics. Here, we review the application of phage-display-derived antibodies in veterinary viral diagnosis, therapeutics, and immunoprophylaxis. These antibodies are also described in <xref rid="antibodies-09-00021-t001" ref-type="table">Table 1</xref> with respect to format, species of origin, and target antigen.</p><sec id="sec3dot1-antibodies-09-00021"><title>3.1. Veterinary Diagnosis</title><p>By using the inherent selection potential of antibody phage display, murine scFv capable of recognizing the avian influenza virus (AIV) was isolated and evaluated through ELISA. It showed higher sensitivity and specificity as compared to the previously established protocols [<xref rid="B35-antibodies-09-00021" ref-type="bibr">35</xref>]. An antibody repertoire of llamas immunized with purified nucleoprotein (AIV-NP) of AIV yielded a novel nanobody (VHH). This VHH led to the development of a lateral flow assay for the rapid detection of AIV [<xref rid="B36-antibodies-09-00021" ref-type="bibr">36</xref>]. Mining of the rabbit antibody repertoire through antibody phage display yielded a novel scFv capable of targeting a conserved motif in the C-terminal of the F2 protein of Newcastle Disease Virus (NDV). This scFv has exceptional diagnostic applications, ensuring rapid pathotyping of NDV isolates [<xref rid="B37-antibodies-09-00021" ref-type="bibr">37</xref>]. Chicken antibody repertoire has also been explored with phage display for the screening of scFv against phosphoprotein (NDV-P) of NDV. This protein is involved in viral RNA replication and transcription, thus presents itself as a potential diagnostic target in control of NDV. An isolated scFv showed higher specificity for NDV-P by ELISA and Western blot [<xref rid="B38-antibodies-09-00021" ref-type="bibr">38</xref>]. Another important virus causing considerable economic losses to the poultry industry is the infectious bursal disease virus (IBDV). Due to a variety of IBDV strains, it was always difficult to distinguish between very virulent IBDV (vvIBDV), classical, variant, and vaccine strains. Sapats and colleagues (2006) isolated a single-chain variable fragment, which efficiently recognizes a highly conformational epitope of VP2 protein of vvIBDV. The efficacy of this mAb in distinguishing vvIBDV from other strains makes it ideal for diagnostic tests like ELISA [<xref rid="B39-antibodies-09-00021" ref-type="bibr">39</xref>,<xref rid="B40-antibodies-09-00021" ref-type="bibr">40</xref>]. Besides chicken, duck has also become a significant part of the worldwide poultry industry. One of the biggest challenges faced by this industry is duck viral hepatitis (DVH) caused by duck hepatitis A virus (DHAV). It is characterized into three serotypes, namely, DHAV-1, DHAV-2, and DHAV-3. Out of these serotypes, DHAV-1 is the most virulent, causing significant widespread losses to this growing industry. Through phage display, a novel nanobody has been isolated after the screening of the camelids antibody repertoire, targeting the VP1 protein of DHAV-1. This nanobody has wide applications in the development of immunoassays for the DHAV-1 diagnosis, such as ELISA [<xref rid="B41-antibodies-09-00021" ref-type="bibr">41</xref>]. </p><p>In the dairy and beef industry, foot and mouth disease (FMD) is considered the most devastating viral disease caused by foot and mouth disease virus (FMDV), inflicting huge economic losses. There are seven serotypes of FMDV, including O, A, C, Asia 1, SAT 1, SAT 2, and SAT 3. New control programs have adopted a combined strategy of exclusion, slaughter, and vaccination. However, the success rate depends upon accurate and reliable differentiation between vaccinated and infected animals. Previously through phage display, murine scFv was isolated against FMDV type O, but it lacked the diagnostics potential in differentiating infected from vaccinated animals [<xref rid="B42-antibodies-09-00021" ref-type="bibr">42</xref>]. To circumvent this bottleneck, recombinant chicken scFv has been isolated against 3ABC protein of FMDV through APD, and its application in ELISA differentiates infected from vaccinated animals [<xref rid="B43-antibodies-09-00021" ref-type="bibr">43</xref>,<xref rid="B44-antibodies-09-00021" ref-type="bibr">44</xref>]. Additionally, murine scFv anti-VP2 of FMDV has demonstrated an efficient diagnostic potential for several FMDV serotypes [<xref rid="B45-antibodies-09-00021" ref-type="bibr">45</xref>]. In the case of the bovine immunodeficiency virus (BIV), murine recombinant antibody in scFv format was generated and showed potential as a detection tool in competitive inhibition ELISA for serological detection of BIV infection in bovines [<xref rid="B46-antibodies-09-00021" ref-type="bibr">46</xref>].</p><p>In pigs, the initial pursuit for new diagnostic tools using recombinant Abs (rAbs) has focused on porcine circovirus type II (PVC2) and classical swine fever. A nanobody (VHH) was obtained from camel immunized with a commercial PVC2 vaccine through APD. The fusion of this VHH with alkaline phosphatase has proved to be an added value in PVC2 diagnosis without any cross-reactivity to PVC1 and porcine reproductive and sensitivity virus (PRRSV) [<xref rid="B47-antibodies-09-00021" ref-type="bibr">47</xref>]. The nanobody has already shown tremendous potential as a promising experimental tool in imaging of porcine epidemic diarrhea virus (PEDV) [<xref rid="B48-antibodies-09-00021" ref-type="bibr">48</xref>]. In addition to this, a highly potent porcinized murine antibody yielded favorable results in diverse diagnostic assays for classical swine fever, while retaining in vitro neutralizing ability [<xref rid="B49-antibodies-09-00021" ref-type="bibr">49</xref>]. Recently, the swine influenza virus (SIV) and PEDV have gained a lot of attention for generating novel binders of diagnostic value through phage display. SIV is a significant pathogen posing serious challenges to swine production. Due to the limitations associated with previous diagnostics tools of SIV infection such as subjectivity, high cost, and lack of suitability on a large scale, VHH was developed through phage display against the conserved nucleoprotein of SIV offering applications in a wide range of immunoassays for SIV diagnosis [<xref rid="B50-antibodies-09-00021" ref-type="bibr">50</xref>]. Similarly, in two separate studies, VHHs were isolated against different target antigens of PEDV, enabling its rapid and sensitive clinical detection. These antibodies are of great added value in the success of the ongoing PEDV control program. PEDV causes huge production losses to the pork industry through a fatal diarrheal disease infecting mainly neonatal and post-weaning piglets [<xref rid="B51-antibodies-09-00021" ref-type="bibr">51</xref>,<xref rid="B52-antibodies-09-00021" ref-type="bibr">52</xref>].</p><p>In dogs, a canine antigen-experienced antibody repertoire has been explored for isolation of scFv with great diagnostic potential against canine parvovirus disease [<xref rid="B53-antibodies-09-00021" ref-type="bibr">53</xref>]. This certainly paves the way for future exploration of canine antibody repertoire for certain applications in canine medicine.</p><p>In horses, the western equine encephalitis virus (WEEV) and the Venezuelan equine encephalitis virus (VEEV) are zoonotic viruses, constantly posing a threat of widespread equine and human epidemics. In early infection of VEEV and WEEV, viral detection is considered as an indicator for the implementation of appropriate prophylaxis such as vaccination to decrease the severity and rapid transmission of the disease. In the pursuit of the ideal detection tools, excavation of murine antibody repertoire has resulted in the isolation of novel scFv, having extensive applications in immunoassays, immunohistochemistry, and radio-immunodiagnostics [<xref rid="B54-antibodies-09-00021" ref-type="bibr">54</xref>,<xref rid="B55-antibodies-09-00021" ref-type="bibr">55</xref>]. </p><p>In sheep, the Maedi-visna virus (MVV), an enveloped non-oncogenic RNA virus, causes a complex syndrome characterized by encephalomyelitis, arthritis, and pneumonitis. Antibody phage display was applied to the synthetic human scFv Griffin.1 library for the isolation of a high-affinity scFv antibody against capsid protein and conserved principal immunodominant domain of transmembrane protein gp46 protein in two separate studies. These scFvs have been proven to be efficient research and diagnostic tools in MVV control programs [<xref rid="B21-antibodies-09-00021" ref-type="bibr">21</xref>,<xref rid="B56-antibodies-09-00021" ref-type="bibr">56</xref>]. In addition to this, an scFv of in vitro veterinary diagnostic importance has been isolated against the blue-tongue virus (BTV) from a large chicken semi-synthetic &#x0201c;Nkuku&#x0201d; antibody phage library [<xref rid="B57-antibodies-09-00021" ref-type="bibr">57</xref>].</p></sec><sec id="sec3dot2-antibodies-09-00021"><title>3.2. Veterinary Therapeutics</title><p>The role of rAbs in veterinary therapeutics is very limited, indicating the need for its expansion by finding new clones capable of targeting viral disease. Mostly in the poultry sector, the therapeutic application of rAbs is considered economically impractical. A prevention strategy against influenza viral infection has been tested by using recombinant adenovirus expressing neutralizing VHH in mice models. An initial study has shown promising results, with a 90%&#x02013;100% survival rate in lethally challenged mice [<xref rid="B58-antibodies-09-00021" ref-type="bibr">58</xref>]. Similarly, a Fab fragment isolated from the chicken antibody repertoire has delineated encouraging results by targeting HA0 hemagglutinin epitopes of highly infectious H5N1 [<xref rid="B59-antibodies-09-00021" ref-type="bibr">59</xref>]. Recently, anti-DHAV-1 scFv has been obtained from a murine antibody repertoire, which harbors the ability to neutralize DHAV-1 by targeting its VP3 protein. The scFv has shown promising therapeutic effects against duck viral hepatitis, a highly infectious disease of ducks with a mortality rate of up to 100% [<xref rid="B60-antibodies-09-00021" ref-type="bibr">60</xref>].</p><p>Bovine viral diarrhea virus (BVDV) is a significant cattle pathogen, inflicting huge economic losses to the livestock industry worldwide. It causes a complex syndrome involving multiple body organs. The sign and symptoms include diarrhea, pneumo-gastroenteritis, abortion, stillbirth, and births of persistently infected calves. To combat this infectious virus, it is imperative to establish novel antivirals to mitigate the devastating economic impinge of this disease in the cattle industry. In this scenario, BVDB NS5B-specific nanobody was obtained through phage display, which is capable of significantly suppressing in vitro BVDV replication. It has demonstrated a promising potential to be an effective anti-BVDV agent [<xref rid="B61-antibodies-09-00021" ref-type="bibr">61</xref>]. Furthermore, in a separate study, a specific nanobody was developed against the E2 protein of BDVD, a protein involved in viral pathogenesis and capable of producing neutralizing antibodies. The efficient binding alongside in vitro neutralization ability makes this anti-E2 nanobody a promising therapeutic candidate in controlling BVDV infection worldwide [<xref rid="B62-antibodies-09-00021" ref-type="bibr">62</xref>].</p><p>In pig farming, transmissible gastroenteritis virus (TGEV) is considered a highly dangerous infectious agent that causes watery diarrhea, vomiting, and ultimately dehydration in pigs. Notably, in piglets, a 100% mortality rate has been observed post-TGEV infection. Recently, a porcine scFv antibody has been identified and characterized, having in vitro TGEV neutralizing ability. The therapeutic potential of this novel binder is promising in the control of porcine viral gastroenteritis [<xref rid="B63-antibodies-09-00021" ref-type="bibr">63</xref>]. Similarly, high-affinity nanobodies targeting Nsp4 and Nsp9 protein of PRRSV with therapeutic potential have been isolated and characterized [<xref rid="B64-antibodies-09-00021" ref-type="bibr">64</xref>,<xref rid="B65-antibodies-09-00021" ref-type="bibr">65</xref>].</p><p>The exploitation of a na&#x000ef;ve llama antibody repertoire resulted in the screening of rabies virus glycoprotein specific VHH, which later led to the generation of homogenous pentavalent multimers called combodies, possessing increased virus-neutralizing capability, following the fusion with coiled&#x02013;coil peptides from human cartilage oligomeric matrix protein [<xref rid="B66-antibodies-09-00021" ref-type="bibr">66</xref>]. In dogs, the therapeutic application of rAbs is mainly restricted to cancer and inflammatory disturbances [<xref rid="B72-antibodies-09-00021" ref-type="bibr">72</xref>]. </p><p>In horses, equine herpesvirus-1 (EHV-1) negatively impinges their welfare and health by causing abortion and respiratory and neurological diseases. Molinkova and colleagues scanned the synthetic human Griffin.1 antibody library for the selection of a highly potent scFv antibody against EHV-1. In vitro EHV-1 neutralization ability of the screened scFv clone makes it an ideal therapeutic candidate [<xref rid="B67-antibodies-09-00021" ref-type="bibr">67</xref>].</p><p>In human medicine, the therapeutic antibodies account for a market of about USD 75 billion [<xref rid="B73-antibodies-09-00021" ref-type="bibr">73</xref>]. In contrast, there exists a great economic disparity when it comes to the therapeutic application of rAbs in veterinary medicine. This demands a continuous search for alternative ways to control viral diseases using rAbs in veterinary medicine by focusing on all animal species.</p></sec><sec id="sec3dot3-antibodies-09-00021"><title>3.3. Veterinary Immunoprophylaxis</title><p>In terms of FMDV prophylactic measure, initial clinical trials of the in vivo application of nanobody-based drugs have shown promising results in guinea pigs, providing them with partial protection against FMDV type O [<xref rid="B68-antibodies-09-00021" ref-type="bibr">68</xref>]. Besides cattle, FMDV infects a wide range of cloven-hoofed animals, including pigs, goats, and sheep. Passive immunization of pigs with a mixture of two novel nanobodies provided them with complete rapid protection from a FMDV challenge, thus improving the FMD immunoprophylactic program [<xref rid="B69-antibodies-09-00021" ref-type="bibr">69</xref>]. Until now, the high level of serotype specificity of these nanobodies renders them exclusive to pigs, thus limiting their application to other species. Furthermore, passive immunization of piglets with anti-PEDV scFv screened from a porcine antibody repertoire has demonstrated encouraging results by providing them complete protection form PEDV infection [<xref rid="B70-antibodies-09-00021" ref-type="bibr">70</xref>]. To date, the implementation of the immunoprophylactic potential of the phage display selected antibodies is limited to pigs; however, the spread of this approach is expected in other species as well in the near future.</p></sec></sec><sec sec-type="conclusions" id="sec4-antibodies-09-00021"><title>4. Conclusions and Future Perspectives</title><p>The inherent potential of combinatorial libraries gives researchers unprecedented control over the expression of the acquired immune system. To date, the prime focus of rAbs has been in veterinary diagnostic applications, ignoring the utilization of their immense therapeutic and immunoprophylactic potential. The diagnostic potential of these monoclonal antibodies is well appreciated, but their therapeutic application against infectious diseases is still a challenge. Although the evolution of antibody engineering has led to highly tailored antibodies with improved pharmacokinetic properties, yet experimental therapeutics remains challenging. For example, the advantages associated with scFv account are a curse in disguise rather than a blessing and render it undesirable for therapeutic application. Small size, low in vivo half-life, rapid clearance, and low stability are the hurdles in the therapeutic avenue. Nevertheless, PEGylation and conjugation of scFv with certain drugs and toxins have circumvented some of the issues for their therapeutic application, but a lot still has to be done. Furthermore, only a few rAb forms have been elucidated in veterinary medicine such as scFv and VHH, while the diagnostic and therapeutic potential of other forms is yet to be explored. In vaccinology, vectored-based scFv delivery for in vivo expression has come out as an effective strategy to sustain the level of antibody fragments in the body. Furthermore, broadly neutralizing antibodies against viral diseases alongside in vivo scFv delivery systems have paved a new avenue of functional reagents, making them more relevant in therapeutics [<xref rid="B74-antibodies-09-00021" ref-type="bibr">74</xref>]. Additionally, advancements in the targeted delivery of rAbs to various novel compartments of the animal body such as the gut, brain, or to the intracellular cytosolic compartment could certainly have a huge impact on the efficacy of antibody therapeutics [<xref rid="B75-antibodies-09-00021" ref-type="bibr">75</xref>]. In the veterinary field, these are just a few examples of implementation of APD, while the vast diagnostic and therapeutic potential of diverse antibody repertoire amongst different species is yet to be explored in relation to the animal diseases. Furthermore, the vast scope of APD technology also encompasses the other areas of immunovirology, such as understanding the pathogenesis of viral infections and their contributing factors. With every passing day, the implementation of this incredible technique is opening new dimensions in immunovirology in terms of pathogenesis, diagnosis, and therapeutics.</p></sec></body><back><notes><title>Author Contributions</title><p>Perspicacity, conceptualization, writing-original draft preparation, editing and reviewing, S.B., and J.P. Both authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding. </p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-antibodies-09-00021"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogenboom</surname><given-names>H.R.</given-names></name><name><surname>De Brune</surname><given-names>A.P.</given-names></name><name><surname>Hufton</surname><given-names>S.E.</given-names></name><name><surname>Hoet</surname><given-names>R.M.</given-names></name><name><surname>Arends</surname><given-names>J.W.</given-names></name><name><surname>Roovers</surname><given-names>R.C.</given-names></name></person-group><article-title>Antibody phage display technology and its applications</article-title><source>Immunotechnology</source><year>1998</year><volume>4</volume><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/S1380-2933(98)00007-4</pub-id><pub-id pub-id-type="pmid">9661810</pub-id></element-citation></ref><ref id="B2-antibodies-09-00021"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmad</surname><given-names>Z.A.</given-names></name><name><surname>Yeap</surname><given-names>S.K.</given-names></name><name><surname>Ali</surname><given-names>A.M.</given-names></name><name><surname>Ho</surname><given-names>W.Y.</given-names></name><name><surname>Alitheen</surname><given-names>N.B.M.</given-names></name><name><surname>Hamid</surname><given-names>M.</given-names></name></person-group><article-title>ScFv antibody: Principles and clinical application</article-title><source>Clin. Dev. Immunol.</source><year>2012</year><volume>2012</volume><fpage>1</fpage><lpage>15</lpage></element-citation></ref><ref id="B3-antibodies-09-00021"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>P.</given-names></name><name><surname>F&#x000fc;hner</surname><given-names>V.</given-names></name><name><surname>Unkauf</surname><given-names>T.</given-names></name><name><surname>Moreira</surname><given-names>G.M.S.G.</given-names></name><name><surname>Frenzel</surname><given-names>A.</given-names></name><name><surname>Miethe</surname><given-names>S.</given-names></name><name><surname>Hust</surname><given-names>M.</given-names></name></person-group><article-title>Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display</article-title><source>Proteom.-Clin. Appl.</source><year>2016</year><volume>10</volume><fpage>922</fpage><lpage>948</lpage></element-citation></ref><ref id="B4-antibodies-09-00021"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hairul Bahara</surname><given-names>N.H.</given-names></name><name><surname>Tye</surname><given-names>G.J.</given-names></name><name><surname>Choong</surname><given-names>Y.S.</given-names></name><name><surname>Ong</surname><given-names>E.B.B.</given-names></name><name><surname>Ismail</surname><given-names>A.</given-names></name><name><surname>Lim</surname><given-names>T.S.</given-names></name></person-group><article-title>Phage display antibodies for diagnostic applications</article-title><source>Biologicals</source><year>2013</year><volume>41</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2013.04.001</pub-id><pub-id pub-id-type="pmid">23647952</pub-id></element-citation></ref><ref id="B5-antibodies-09-00021"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burkovitz</surname><given-names>A.</given-names></name><name><surname>Ofran</surname><given-names>Y.</given-names></name></person-group><article-title>Understanding differences between synthetic and natural antibodies can help improve antibody engineering</article-title><source>MAbs</source><year>2016</year><volume>8</volume><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1080/19420862.2015.1123365</pub-id><pub-id pub-id-type="pmid">26652053</pub-id></element-citation></ref><ref id="B6-antibodies-09-00021"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tohidkia</surname><given-names>M.R.</given-names></name><name><surname>Barar</surname><given-names>J.</given-names></name><name><surname>Asadi</surname><given-names>F.</given-names></name><name><surname>Omidi</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular considerations for development of phage antibody libraries</article-title><source>J. Drug Target.</source><year>2012</year><volume>20</volume><fpage>195</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.3109/1061186X.2011.611517</pub-id><pub-id pub-id-type="pmid">21950316</pub-id></element-citation></ref><ref id="B7-antibodies-09-00021"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>G.P.</given-names></name></person-group><article-title>Preface. Surface display and peptide libraries</article-title><source>Gene</source><year>1993</year><volume>128</volume><fpage>1</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/0378-1119(93)90145-S</pub-id><pub-id pub-id-type="pmid">8508950</pub-id></element-citation></ref><ref id="B8-antibodies-09-00021"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>J.N.</given-names></name><name><surname>Model</surname><given-names>P.</given-names></name><name><surname>Russel</surname><given-names>M.</given-names></name></person-group><article-title>A trans-envelope protein complex needed for filamentous phage assembly and export</article-title><source>Mol. Microbiol.</source><year>1999</year><volume>34</volume><fpage>745</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2958.1999.01636.x</pub-id><pub-id pub-id-type="pmid">10564514</pub-id></element-citation></ref><ref id="B9-antibodies-09-00021"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carlsson</surname><given-names>F.</given-names></name><name><surname>Trilling</surname><given-names>M.</given-names></name><name><surname>Perez</surname><given-names>F.</given-names></name><name><surname>Ohlin</surname><given-names>M.</given-names></name></person-group><article-title>A dimerized single-chain variable fragment system for the assessment of neutralizing activity of phage display-selected antibody fragments specific for cytomegalovirus</article-title><source>J. Immunol. Methods</source><year>2012</year><volume>376</volume><fpage>68</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2011.11.010</pub-id></element-citation></ref><ref id="B10-antibodies-09-00021"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>K.</given-names></name><name><surname>N&#x000f6;lke</surname><given-names>G.</given-names></name><name><surname>Schillberg</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name><name><surname>Wu</surname><given-names>C.</given-names></name><name><surname>Jiang</surname><given-names>H.</given-names></name><name><surname>Meng</surname><given-names>H.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name></person-group><article-title>Improved fluoroquinolone detection in ELISA through engineering of a broad-specific single-chain variable fragment binding simultaneously to 20 fluoroquinolones</article-title><source>Anal. Bioanal. Chem.</source><year>2012</year><volume>403</volume><fpage>2771</fpage><lpage>2783</lpage><pub-id pub-id-type="doi">10.1007/s00216-012-6062-z</pub-id><pub-id pub-id-type="pmid">22549819</pub-id></element-citation></ref><ref id="B11-antibodies-09-00021"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>T.</given-names></name><name><surname>Onodera</surname><given-names>K.</given-names></name><name><surname>Kamijo</surname><given-names>S.</given-names></name></person-group><article-title>Identification of novel short peptide inhibitors of soluble 37/48 kDa oligomers of amyloid &#x003b2;42</article-title><source>Biosci. Biotechnol. Biochem.</source><year>2011</year><volume>75</volume><fpage>1496</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1271/bbb.110198</pub-id><?supplied-pmid 21821948?><pub-id pub-id-type="pmid">21821948</pub-id></element-citation></ref><ref id="B12-antibodies-09-00021"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimazaki</surname><given-names>K.</given-names></name><name><surname>Lepin</surname><given-names>E.J.</given-names></name><name><surname>Wei</surname><given-names>B.</given-names></name><name><surname>Nagy</surname><given-names>A.K.</given-names></name><name><surname>Coulam</surname><given-names>C.P.</given-names></name><name><surname>Mareninov</surname><given-names>S.</given-names></name><name><surname>Fu</surname><given-names>M.</given-names></name><name><surname>Wu</surname><given-names>A.M.</given-names></name><name><surname>Marks</surname><given-names>J.D.</given-names></name><name><surname>Braun</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines</article-title><source>Clin. Cancer Res.</source><year>2008</year><volume>14</volume><fpage>7367</fpage><lpage>7377</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1016</pub-id><?supplied-pmid 19010852?><pub-id pub-id-type="pmid">19010852</pub-id></element-citation></ref><ref id="B13-antibodies-09-00021"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Azzazy</surname><given-names>H.M.E.</given-names></name><name><surname>Highsmith</surname><given-names>W.E.</given-names></name></person-group><article-title>Phage display technology: Clinical applications and recent innovations</article-title><source>Clin. Biochem.</source><year>2002</year><volume>35</volume><fpage>425</fpage><lpage>445</lpage><pub-id pub-id-type="doi">10.1016/S0009-9120(02)00343-0</pub-id><pub-id pub-id-type="pmid">12413604</pub-id></element-citation></ref><ref id="B14-antibodies-09-00021"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmen</surname><given-names>S.</given-names></name><name><surname>Jermutus</surname><given-names>L.</given-names></name></person-group><article-title>Concepts in antibody phage display</article-title><source>Brief. Funct. Genom. Proteom.</source><year>2002</year><volume>1</volume><fpage>189</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1093/bfgp/1.2.189</pub-id><?supplied-pmid 15239904?><pub-id pub-id-type="pmid">15239904</pub-id></element-citation></ref><ref id="B15-antibodies-09-00021"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>B.</given-names></name><name><surname>Schulz</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Sierks</surname><given-names>M.R.</given-names></name></person-group><article-title>Improved affinity selection using phage display technology and off-rate based selection</article-title><source>Electron. J. Biotechnol.</source><year>2006</year><volume>9</volume><pub-id pub-id-type="doi">10.2225/vol9-issue2-fulltext-6</pub-id></element-citation></ref><ref id="B16-antibodies-09-00021"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knappik</surname><given-names>A.</given-names></name><name><surname>Ge</surname><given-names>L.</given-names></name><name><surname>Honegger</surname><given-names>A.</given-names></name><name><surname>Pack</surname><given-names>P.</given-names></name><name><surname>Fischer</surname><given-names>M.</given-names></name><name><surname>Wellnhofer</surname><given-names>G.</given-names></name><name><surname>Hoess</surname><given-names>A.</given-names></name><name><surname>W&#x000f6;lle</surname><given-names>J.</given-names></name><name><surname>Pl&#x000fc;ckthun</surname><given-names>A.</given-names></name><name><surname>Virnek&#x000e4;s</surname><given-names>B.</given-names></name></person-group><article-title>Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides</article-title><source>J. Mol. Biol.</source><year>2000</year><volume>296</volume><fpage>57</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1999.3444</pub-id><pub-id pub-id-type="pmid">10656818</pub-id></element-citation></ref><ref id="B17-antibodies-09-00021"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidhu</surname><given-names>S.S.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Fellouse</surname><given-names>F.A.</given-names></name><name><surname>Eigenbrot</surname><given-names>C.</given-names></name><name><surname>Fuh</surname><given-names>G.</given-names></name></person-group><article-title>Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions</article-title><source>J. Mol. Biol.</source><year>2004</year><volume>338</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2004.02.050</pub-id><pub-id pub-id-type="pmid">15066433</pub-id></element-citation></ref><ref id="B18-antibodies-09-00021"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McWhirter</surname><given-names>J.R.</given-names></name><name><surname>Kretz-Rommel</surname><given-names>A.</given-names></name><name><surname>Saven</surname><given-names>A.</given-names></name><name><surname>Maruyama</surname><given-names>T.</given-names></name><name><surname>Potter</surname><given-names>K.M.</given-names></name><name><surname>Mockridge</surname><given-names>C.I.</given-names></name><name><surname>Ravey</surname><given-names>E.P.</given-names></name><name><surname>Qin</surname><given-names>F.</given-names></name><name><surname>Bowdish</surname><given-names>K.S.</given-names></name></person-group><article-title>Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2006</year><volume>103</volume><fpage>1041</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1073/pnas.0510081103</pub-id><pub-id pub-id-type="pmid">16418292</pub-id></element-citation></ref><ref id="B19-antibodies-09-00021"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomonosova</surname><given-names>A.V.</given-names></name><name><surname>Laman</surname><given-names>A.G.</given-names></name><name><surname>Fursova</surname><given-names>K.K.</given-names></name><name><surname>Shepelyakovskaya</surname><given-names>A.O.</given-names></name><name><surname>Vertiev</surname><given-names>Y.V.</given-names></name><name><surname>Brovko</surname><given-names>F.A.</given-names></name><name><surname>Grishin</surname><given-names>E.V.</given-names></name></person-group><article-title>Generation of scFv phages specific to Staphylococcus enterotoxin C1 by panning on related antigens</article-title><source>MAbs</source><year>2011</year><volume>3</volume><fpage>513</fpage><lpage>516</lpage><pub-id pub-id-type="doi">10.4161/mabs.3.6.18089</pub-id><pub-id pub-id-type="pmid">22123058</pub-id></element-citation></ref><ref id="B20-antibodies-09-00021"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W.</given-names></name><name><surname>Samanta</surname><given-names>M.</given-names></name><name><surname>Crawford</surname><given-names>S.E.</given-names></name><name><surname>Estes</surname><given-names>M.K.</given-names></name><name><surname>Neill</surname><given-names>F.H.</given-names></name><name><surname>Atmar</surname><given-names>R.L.</given-names></name><name><surname>Palzkill</surname><given-names>T.</given-names></name><name><surname>Burton</surname><given-names>D.</given-names></name></person-group><article-title>Identification of human single-chain antibodies with broad reactivity for noroviruses</article-title><source>Protein Eng. Des. Sel.</source><year>2014</year><volume>27</volume><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1093/protein/gzu023</pub-id><pub-id pub-id-type="pmid">24946948</pub-id></element-citation></ref><ref id="B21-antibodies-09-00021"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazek</surname><given-names>D.</given-names></name><name><surname>Celer</surname><given-names>V.</given-names></name><name><surname>Navr&#x000e1;tilov&#x000e1;</surname><given-names>I.</given-names></name><name><surname>Skl&#x000e1;dal</surname><given-names>P.</given-names></name></person-group><article-title>Generation and characterization of single-chain antibody fragments specific against transmembrane envelope glycoprotein gp46 of maedi-visna virus</article-title><source>J. Virol. Methods</source><year>2004</year><volume>115</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2003.09.020</pub-id><?supplied-pmid 14656464?><pub-id pub-id-type="pmid">14656464</pub-id></element-citation></ref><ref id="B22-antibodies-09-00021"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osbourn</surname><given-names>J.K.</given-names></name><name><surname>Derbyshire</surname><given-names>E.J.</given-names></name><name><surname>Vaughan</surname><given-names>T.J.</given-names></name><name><surname>Field</surname><given-names>A.W.</given-names></name><name><surname>Johnson</surname><given-names>K.S.</given-names></name></person-group><article-title>Pathfinder selection: In situ isolation of novel antibodies</article-title><source>Immunotechnology</source><year>1998</year><volume>3</volume><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/S1380-2933(97)10007-0</pub-id><pub-id pub-id-type="pmid">9530562</pub-id></element-citation></ref><ref id="B23-antibodies-09-00021"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoogenboom</surname><given-names>H.R.</given-names></name><name><surname>Lutgerink</surname><given-names>J.T.</given-names></name><name><surname>Pelsers</surname><given-names>M.M.A.L.</given-names></name><name><surname>Rousch</surname><given-names>M.J.M.M.</given-names></name><name><surname>Coote</surname><given-names>J.</given-names></name><name><surname>Van Neer</surname><given-names>N.</given-names></name><name><surname>De Bru&#x000ef;ne</surname><given-names>A.</given-names></name><name><surname>Van Nieuwenhoven</surname><given-names>F.A.</given-names></name><name><surname>Glatz</surname><given-names>J.F.C.</given-names></name><name><surname>Arends</surname><given-names>J.W.</given-names></name></person-group><article-title>Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library</article-title><source>Eur. J. Biochem.</source><year>1999</year><volume>260</volume><fpage>774</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.1999.00214.x</pub-id><?supplied-pmid 10103007?><pub-id pub-id-type="pmid">10103007</pub-id></element-citation></ref><ref id="B24-antibodies-09-00021"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dominik</surname><given-names>P.K.</given-names></name><name><surname>Borowska</surname><given-names>M.T.</given-names></name><name><surname>Dalmas</surname><given-names>O.</given-names></name><name><surname>Kim</surname><given-names>S.S.</given-names></name><name><surname>Perozo</surname><given-names>E.</given-names></name><name><surname>Keenan</surname><given-names>R.J.</given-names></name><name><surname>Kossiakoff</surname><given-names>A.A.</given-names></name></person-group><article-title>Conformational Chaperones for Structural Studies of Membrane Proteins Using Antibody Phage Display with Nanodiscs</article-title><source>Structure</source><year>2016</year><volume>24</volume><fpage>300</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.1016/j.str.2015.11.014</pub-id><pub-id pub-id-type="pmid">26749445</pub-id></element-citation></ref><ref id="B25-antibodies-09-00021"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlidou</surname><given-names>M.</given-names></name><name><surname>H&#x000e4;nel</surname><given-names>K.</given-names></name><name><surname>M&#x000f6;ckel</surname><given-names>L.</given-names></name><name><surname>Willbold</surname><given-names>D.</given-names></name></person-group><article-title>Nanodiscs Allow Phage Display Selection for Ligands to Non-Linear Epitopes on Membrane Proteins</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e72272</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0072272</pub-id><pub-id pub-id-type="pmid">24039747</pub-id></element-citation></ref><ref id="B26-antibodies-09-00021"><label>26.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dominik</surname><given-names>P.K.</given-names></name><name><surname>Kossiakoff</surname><given-names>A.A.</given-names></name></person-group><article-title>Phage display selections for affinity reagents to membrane proteins in nanodiscs</article-title><source>Methods in Enzymology</source><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2015</year></element-citation></ref><ref id="B27-antibodies-09-00021"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jespersen</surname><given-names>L.K.</given-names></name><name><surname>Kuusinen</surname><given-names>A.</given-names></name><name><surname>Orellana</surname><given-names>A.</given-names></name><name><surname>Kein&#x000e4;nen</surname><given-names>K.</given-names></name><name><surname>Engberg</surname><given-names>J.</given-names></name></person-group><article-title>Use of proteoliposomes to generate phage antibodies against native AMPA receptor</article-title><source>Eur. J. Biochem.</source><year>2000</year><volume>267</volume><fpage>1382</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1046/j.1432-1327.2000.01137.x</pub-id><pub-id pub-id-type="pmid">10691975</pub-id></element-citation></ref><ref id="B28-antibodies-09-00021"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thrane</surname><given-names>S.</given-names></name><name><surname>Janitzek</surname><given-names>C.M.</given-names></name><name><surname>Agerb&#x000e6;k</surname><given-names>M.</given-names></name><name><surname>Ditlev</surname><given-names>S.B.</given-names></name><name><surname>Resende</surname><given-names>M.</given-names></name><name><surname>Nielsen</surname><given-names>M.A.</given-names></name><name><surname>Theander</surname><given-names>T.G.</given-names></name><name><surname>Salanti</surname><given-names>A.</given-names></name><name><surname>Sander</surname><given-names>A.F.</given-names></name></person-group><article-title>A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0143071</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0143071</pub-id><pub-id pub-id-type="pmid">26599509</pub-id></element-citation></ref><ref id="B29-antibodies-09-00021"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glanville</surname><given-names>J.</given-names></name><name><surname>D&#x02019;Angelo</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>T.A.</given-names></name><name><surname>Reddy</surname><given-names>S.T.</given-names></name><name><surname>Naranjo</surname><given-names>L.</given-names></name><name><surname>Ferrara</surname><given-names>F.</given-names></name><name><surname>Bradbury</surname><given-names>A.R.M.</given-names></name></person-group><article-title>Deep sequencing in library selection projects: What insight does it bring?</article-title><source>Curr. Opin. Struct. Biol.</source><year>2015</year><volume>33</volume><fpage>146</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2015.09.001</pub-id><pub-id pub-id-type="pmid">26451649</pub-id></element-citation></ref><ref id="B30-antibodies-09-00021"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>N.</given-names></name></person-group><article-title>Sequencing antibody repertoires: The next generation</article-title><source>MAbs</source><publisher-name>Taylor &#x00026; Francis</publisher-name><publisher-loc>Milton Park, Milton, UK</publisher-loc><publisher-loc>Abingdon, UK</publisher-loc><year>2011</year></element-citation></ref><ref id="B31-antibodies-09-00021"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meli</surname><given-names>G.</given-names></name><name><surname>Visintin</surname><given-names>M.</given-names></name><name><surname>Cannistraci</surname><given-names>I.</given-names></name><name><surname>Cattaneo</surname><given-names>A.</given-names></name></person-group><article-title>Direct in Vivo Intracellular Selection of Conformation-sensitive Antibody Domains Targeting Alzheimer&#x02019;s Amyloid-&#x003b2; Oligomers</article-title><source>J. Mol. Biol.</source><year>2009</year><volume>387</volume><fpage>584</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.01.061</pub-id><pub-id pub-id-type="pmid">19361429</pub-id></element-citation></ref><ref id="B32-antibodies-09-00021"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>T.</given-names></name><name><surname>Rabbitts</surname><given-names>T.H.</given-names></name></person-group><article-title>Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture</article-title><source>Nat. Protoc.</source><year>2010</year><volume>5</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1038/nprot.2009.199</pub-id><pub-id pub-id-type="pmid">20057382</pub-id></element-citation></ref><ref id="B33-antibodies-09-00021"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fantini</surname><given-names>M.</given-names></name><name><surname>Pandolfini</surname><given-names>L.</given-names></name><name><surname>Lisi</surname><given-names>S.</given-names></name><name><surname>Chirichella</surname><given-names>M.</given-names></name><name><surname>Arisi</surname><given-names>I.</given-names></name><name><surname>Terrigno</surname><given-names>M.</given-names></name><name><surname>Goracci</surname><given-names>M.</given-names></name><name><surname>Cremisi</surname><given-names>F.</given-names></name><name><surname>Cattaneo</surname><given-names>A.</given-names></name></person-group><article-title>Assessment of antibody library diversity through next generation sequencing and technical error compensation</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0177574</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0177574</pub-id><?supplied-pmid 28505201?><pub-id pub-id-type="pmid">28505201</pub-id></element-citation></ref><ref id="B34-antibodies-09-00021"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zinkernagel</surname><given-names>R.M.</given-names></name></person-group><article-title>Immunology taught by viruses</article-title><source>Science (80-.)</source><year>1996</year><volume>271</volume><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1126/science.271.5246.173</pub-id><?supplied-pmid 8539616?><pub-id pub-id-type="pmid">8539616</pub-id></element-citation></ref><ref id="B35-antibodies-09-00021"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>D.</given-names></name><name><surname>Shaikh</surname><given-names>A.</given-names></name><name><surname>Bhatia</surname><given-names>S.</given-names></name><name><surname>Pateriya</surname><given-names>A.K.</given-names></name><name><surname>Khandia</surname><given-names>R.</given-names></name><name><surname>Sood</surname><given-names>R.</given-names></name><name><surname>Prakash</surname><given-names>A.</given-names></name><name><surname>Pattnaik</surname><given-names>B.</given-names></name><name><surname>Pradhan</surname><given-names>H.K.</given-names></name></person-group><article-title>Development of single-chain Fv against the nucleoprotein of type A influenza virus and its use in ELISA</article-title><source>J. Virol. Methods</source><year>2014</year><volume>208</volume><fpage>129</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2014.08.009</pub-id><?supplied-pmid 25152529?><pub-id pub-id-type="pmid">25152529</pub-id></element-citation></ref><ref id="B36-antibodies-09-00021"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>K.</given-names></name><name><surname>Yu</surname><given-names>W.L.</given-names></name><name><surname>Lin</surname><given-names>M.</given-names></name><name><surname>Davis</surname><given-names>S.A.N.</given-names></name><name><surname>Elmgren</surname><given-names>C.</given-names></name><name><surname>MacKenzie</surname><given-names>R.</given-names></name><name><surname>Tanha</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Dubuc</surname><given-names>G.</given-names></name><name><surname>Brown</surname><given-names>E.G.</given-names></name><etal/></person-group><article-title>Prototype single step lateral flow technology for detection of avian influenza virus and chicken antibody to avian influenza virus</article-title><source>J. Immunoass. Immunochem.</source><year>2007</year><volume>28</volume><fpage>307</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1080/15321810701603443</pub-id></element-citation></ref><ref id="B37-antibodies-09-00021"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Collins</surname><given-names>M.S.</given-names></name><name><surname>Whitelam</surname><given-names>G.C.</given-names></name><name><surname>Alexander</surname><given-names>D.J.</given-names></name></person-group><article-title>Rapid pathotyping of Newcastle disease virus using a single-chain Fv displayed on phage against the C-terminal end of the F2 polypeptide</article-title><source>Arch. Virol.</source><year>2002</year><volume>147</volume><fpage>2025</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1007/s00705-002-0862-y</pub-id><pub-id pub-id-type="pmid">12376763</pub-id></element-citation></ref><ref id="B38-antibodies-09-00021"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Ye</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Jia</surname><given-names>R.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>Selection and characterization of single-chain recombinant antibodies against phosphoprotein of newcastle disease virus</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>285</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2014.05.006</pub-id><pub-id pub-id-type="pmid">25018092</pub-id></element-citation></ref><ref id="B39-antibodies-09-00021"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapats</surname><given-names>S.I.</given-names></name><name><surname>Trinidad</surname><given-names>L.</given-names></name><name><surname>Gould</surname><given-names>G.</given-names></name><name><surname>Heine</surname><given-names>H.G.</given-names></name><name><surname>Van Den Berg</surname><given-names>T.P.</given-names></name><name><surname>Eterradossi</surname><given-names>N.</given-names></name><name><surname>Jackwood</surname><given-names>D.</given-names></name><name><surname>Parede</surname><given-names>L.</given-names></name><name><surname>Toquin</surname><given-names>D.</given-names></name><name><surname>Ignjatovic</surname><given-names>J.</given-names></name></person-group><article-title>Chicken recombinant antibodies specific for very virulent infectious bursal disease virus</article-title><source>Arch. Virol.</source><year>2006</year><volume>151</volume><fpage>1551</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1007/s00705-006-0729-8</pub-id><pub-id pub-id-type="pmid">16514499</pub-id></element-citation></ref><ref id="B40-antibodies-09-00021"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapats</surname><given-names>S.</given-names></name><name><surname>Gould</surname><given-names>G.</given-names></name><name><surname>Trinidad</surname><given-names>L.</given-names></name><name><surname>Parede</surname><given-names>L.H.</given-names></name><name><surname>David</surname><given-names>C.</given-names></name><name><surname>Ignjatovic</surname><given-names>J.</given-names></name></person-group><article-title>An ELISA for detection of infectious bursal disease virus and differentiation of very virulent strains based on single chain recombinant chicken antibodies</article-title><source>Avian Pathol.</source><year>2005</year><volume>34</volume><fpage>449</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1080/03079450500367765</pub-id><pub-id pub-id-type="pmid">16537158</pub-id></element-citation></ref><ref id="B41-antibodies-09-00021"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Zhao</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>R.</given-names></name><name><surname>Lan</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Xie</surname><given-names>Z.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Identification and characterization of a novel nanobody against duck hepatitis A virus type 1</article-title><source>Virology</source><year>2019</year><volume>528</volume><fpage>101</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2018.12.013</pub-id><pub-id pub-id-type="pmid">30590261</pub-id></element-citation></ref><ref id="B42-antibodies-09-00021"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ShengFeng</surname><given-names>C.</given-names></name><name><surname>Ping</surname><given-names>L.</given-names></name><name><surname>Tao</surname><given-names>S.</given-names></name><name><surname>Xin</surname><given-names>W.</given-names></name><name><surname>GuoFeng</surname><given-names>W.</given-names></name></person-group><article-title>Construction, expression, purification, refold and activity assay of a specific scFv fragment against foot and mouth disease virus</article-title><source>Vet. Res. Commun.</source><year>2003</year><volume>27</volume><fpage>243</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1023/A:1023300825438</pub-id><pub-id pub-id-type="pmid">12777098</pub-id></element-citation></ref><ref id="B43-antibodies-09-00021"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>G.K.</given-names></name><name><surname>Mahajan</surname><given-names>S.</given-names></name><name><surname>Matura</surname><given-names>R.</given-names></name><name><surname>Subramaniam</surname><given-names>S.</given-names></name><name><surname>Mohapatra</surname><given-names>J.K.</given-names></name><name><surname>Pattnaik</surname><given-names>B.</given-names></name></person-group><article-title>Production and characterization of single-chain antibody (scFv) against 3ABC non-structural protein in Escherichia coli for sero-diagnosis of Foot and Mouth Disease virus</article-title><source>Biologicals</source><year>2014</year><volume>42</volume><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2014.08.005</pub-id><pub-id pub-id-type="pmid">25439091</pub-id></element-citation></ref><ref id="B44-antibodies-09-00021"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foord</surname><given-names>A.J.</given-names></name><name><surname>Muller</surname><given-names>J.D.</given-names></name><name><surname>Yu</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>L.F.</given-names></name><name><surname>Heine</surname><given-names>H.G.</given-names></name></person-group><article-title>Production and application of recombinant antibodies to foot-and-mouth disease virus non-structural protein 3ABC</article-title><source>J. Immunol. Methods</source><year>2007</year><volume>321</volume><fpage>142</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2007.01.014</pub-id><pub-id pub-id-type="pmid">17328909</pub-id></element-citation></ref><ref id="B45-antibodies-09-00021"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salem</surname><given-names>R.</given-names></name><name><surname>El-Kholy</surname><given-names>A.A.</given-names></name><name><surname>Ibrahim</surname><given-names>M.</given-names></name></person-group><article-title>Eight novel single chain antibody fragments recognising VP2 of foot-and-mouth disease virus serotypes A, O, and SAT 2</article-title><source>Virology</source><year>2019</year><volume>533</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2019.05.012</pub-id><pub-id pub-id-type="pmid">31170612</pub-id></element-citation></ref><ref id="B46-antibodies-09-00021"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>S.</given-names></name><name><surname>Gangil</surname><given-names>R.</given-names></name><name><surname>Gupta</surname><given-names>D.S.</given-names></name><name><surname>Sood</surname><given-names>R.</given-names></name><name><surname>Pradhan</surname><given-names>H.K.</given-names></name><name><surname>Dubey</surname><given-names>S.C.</given-names></name></person-group><article-title>Single-chain fragment variable antibody against the capsid protein of bovine immunodeficiency virus and its use in ELISA</article-title><source>J. Virol. Methods</source><year>2010</year><volume>167</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2010.03.012</pub-id><pub-id pub-id-type="pmid">20304014</pub-id></element-citation></ref><ref id="B47-antibodies-09-00021"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name><name><surname>Gong</surname><given-names>Z.</given-names></name><name><surname>Serge</surname><given-names>M.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name></person-group><article-title>A phage-displayed single domain antibody fused to alkaline phosphatase for detection of porcine circovirus type 2</article-title><source>J. Virol. Methods</source><year>2015</year><volume>213</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2014.11.023</pub-id><pub-id pub-id-type="pmid">25512132</pub-id></element-citation></ref><ref id="B48-antibodies-09-00021"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Yin</surname><given-names>S.</given-names></name><name><surname>Shang</surname><given-names>Y.</given-names></name><name><surname>Khan</surname><given-names>M.U.Z.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Yuan</surname><given-names>L.</given-names></name><name><surname>Gao</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>J.</given-names></name></person-group><article-title>Single-domain antibodies as promising experimental tools in imaging and isolation of porcine epidemic diarrhea virus</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>8931</fpage><lpage>8942</lpage><pub-id pub-id-type="doi">10.1007/s00253-018-9324-7</pub-id><pub-id pub-id-type="pmid">30143837</pub-id></element-citation></ref><ref id="B49-antibodies-09-00021"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Sun</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Ji</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Luo</surname><given-names>Y.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Expression and characterization of a recombinant porcinized antibody against the E2 protein of classical swine fever virus</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2018</year><volume>102</volume><fpage>961</fpage><lpage>970</lpage><pub-id pub-id-type="doi">10.1007/s00253-017-8647-0</pub-id><pub-id pub-id-type="pmid">29184988</pub-id></element-citation></ref><ref id="B50-antibodies-09-00021"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>T.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Fang</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>E.M.</given-names></name></person-group><article-title>Biotinylated single-domain antibody-based blocking ELISA for detection of antibodies against swine influenza virus</article-title><source>Int. J. Nanomed.</source><year>2019</year><volume>14</volume><fpage>9337</fpage><pub-id pub-id-type="doi">10.2147/IJN.S218458</pub-id></element-citation></ref><ref id="B51-antibodies-09-00021"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>F.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Na</surname><given-names>A.M.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Cao</surname><given-names>J.</given-names></name><name><surname>Du</surname><given-names>Y.</given-names></name></person-group><article-title>Preparation and characterization of a single-domain antibody specific for the porcine epidemic diarrhea virus spike protein</article-title><source>AMB Express</source><year>2019</year><volume>9</volume><fpage>104</fpage><pub-id pub-id-type="doi">10.1186/s13568-019-0834-1</pub-id><pub-id pub-id-type="pmid">31300902</pub-id></element-citation></ref><ref id="B52-antibodies-09-00021"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name><name><surname>Tian</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name></person-group><article-title>A novel biotinylated nanobody-based blocking ELISA for the rapid and sensitive clinical detection of porcine epidemic diarrhea virus</article-title><source>J. Nanobiotechnol.</source><year>2019</year><volume>17</volume><fpage>96</fpage><pub-id pub-id-type="doi">10.1186/s12951-019-0531-x</pub-id></element-citation></ref><ref id="B53-antibodies-09-00021"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braganza</surname><given-names>A.</given-names></name><name><surname>Wallace</surname><given-names>K.</given-names></name><name><surname>Pell</surname><given-names>L.</given-names></name><name><surname>Parrish</surname><given-names>C.R.</given-names></name><name><surname>Siegel</surname><given-names>D.L.</given-names></name><name><surname>Mason</surname><given-names>N.J.</given-names></name></person-group><article-title>Generation and validation of canine single chain variable fragment phage display libraries</article-title><source>Vet. Immunol. Immunopathol.</source><year>2011</year><volume>139</volume><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2010.07.026</pub-id><?supplied-pmid 20817275?><pub-id pub-id-type="pmid">20817275</pub-id></element-citation></ref><ref id="B54-antibodies-09-00021"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>M.C.</given-names></name><name><surname>Jager</surname><given-names>S.</given-names></name><name><surname>Mah</surname><given-names>D.C.W.</given-names></name><name><surname>Jebailey</surname><given-names>L.</given-names></name><name><surname>Mah</surname><given-names>M.A.</given-names></name><name><surname>Masri</surname><given-names>S.A.</given-names></name><name><surname>Nagata</surname><given-names>L.P.</given-names></name></person-group><article-title>Construction and characterization of a novel recombinant single-chain variable fragment antibody against Western equine encephalitis virus</article-title><source>Hybridoma</source><year>2000</year><volume>19</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1089/027245700315743</pub-id><pub-id pub-id-type="pmid">10768836</pub-id></element-citation></ref><ref id="B55-antibodies-09-00021"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duggan</surname><given-names>J.M.</given-names></name><name><surname>Coates</surname><given-names>D.M.</given-names></name><name><surname>Ulaeto</surname><given-names>D.O.</given-names></name></person-group><article-title>Isolation of single-chain antibody fragments against Venezuelan equine encephalomyelitis virus from two different immune sources</article-title><source>Viral Immunol.</source><year>2001</year><volume>14</volume><fpage>263</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1089/088282401753266774</pub-id><?supplied-pmid 11572636?><pub-id pub-id-type="pmid">11572636</pub-id></element-citation></ref><ref id="B56-antibodies-09-00021"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Celer</surname><given-names>V.</given-names></name><name><surname>Bla&#x0017e;ek</surname><given-names>D.</given-names></name><name><surname>Navr&#x000e1;tilov&#x000e1;</surname><given-names>I.</given-names></name><name><surname>Skl&#x000e1;dal</surname><given-names>P.</given-names></name><name><surname>Blacklaws</surname><given-names>B.</given-names></name><name><surname>Bujdoso</surname><given-names>R.</given-names></name></person-group><article-title>Recombinant single-chain Fv antibodies that recognize the p25 protein of the maedi-visna virus</article-title><source>Folia Microbiol. (Praha)</source><year>2003</year><volume>48</volume><fpage>435</fpage><pub-id pub-id-type="doi">10.1007/BF02931380</pub-id><pub-id pub-id-type="pmid">12879760</pub-id></element-citation></ref><ref id="B57-antibodies-09-00021"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Wyngaardt</surname><given-names>W.</given-names></name><name><surname>Malatji</surname><given-names>T.</given-names></name><name><surname>Mashau</surname><given-names>C.</given-names></name><name><surname>Fehrsen</surname><given-names>J.</given-names></name><name><surname>Jordaan</surname><given-names>F.</given-names></name><name><surname>Miltiadou</surname><given-names>D.</given-names></name><name><surname>du Plessis</surname><given-names>D.H.</given-names></name></person-group><article-title>A large semi-synthetic single-chain Fv phage display library based on chicken immunoglobulin genes</article-title><source>BMC Biotechnol.</source><year>2004</year><volume>4</volume><elocation-id>6</elocation-id><pub-id pub-id-type="doi">10.1186/1472-6750-4-6</pub-id><pub-id pub-id-type="pmid">15059288</pub-id></element-citation></ref><ref id="B58-antibodies-09-00021"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tutykhina</surname><given-names>I.L.</given-names></name><name><surname>Sedova</surname><given-names>E.S.</given-names></name><name><surname>Gribova</surname><given-names>I.Y.</given-names></name><name><surname>Ivanova</surname><given-names>T.I.</given-names></name><name><surname>Vasilev</surname><given-names>L.A.</given-names></name><name><surname>Rutovskaya</surname><given-names>M.V.</given-names></name><name><surname>Lysenko</surname><given-names>A.A.</given-names></name><name><surname>Shmarov</surname><given-names>M.M.</given-names></name><name><surname>Logunov</surname><given-names>D.Y.</given-names></name><name><surname>Naroditsky</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Passive immunization with a recombinant adenovirus expressing an HA (H5)-specific single-domain antibody protects mice from lethal influenza infection</article-title><source>Antivir. Res.</source><year>2013</year><volume>97</volume><fpage>318</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2012.12.021</pub-id><pub-id pub-id-type="pmid">23274786</pub-id></element-citation></ref><ref id="B59-antibodies-09-00021"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitaksajjakul</surname><given-names>P.</given-names></name><name><surname>Lekcharoensuk</surname><given-names>P.</given-names></name><name><surname>Upragarin</surname><given-names>N.</given-names></name><name><surname>Barbas</surname><given-names>C.F.</given-names></name><name><surname>Ibrahim</surname><given-names>M.S.</given-names></name><name><surname>Ikuta</surname><given-names>K.</given-names></name><name><surname>Ramasoota</surname><given-names>P.</given-names></name></person-group><article-title>Fab MAbs specific to HA of influenza virus with H5N1 neutralizing activity selected from immunized chicken phage library</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2010</year><volume>395</volume><fpage>496</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.04.040</pub-id><pub-id pub-id-type="pmid">20382115</pub-id></element-citation></ref><ref id="B60-antibodies-09-00021"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Cui</surname><given-names>P.</given-names></name><name><surname>Zhu</surname><given-names>S.</given-names></name><name><surname>Meng</surname><given-names>T.</given-names></name><name><surname>Hao</surname><given-names>F.</given-names></name><name><surname>Zhu</surname><given-names>G.</given-names></name><name><surname>Zuo</surname><given-names>W.</given-names></name></person-group><article-title>Preparation of single-chain antibody against VP3 protein of duck hepatitis virus type 1 by phage display technology</article-title><source>J. Virol. Methods</source><year>2018</year><volume>257</volume><fpage>73</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2018.04.010</pub-id><pub-id pub-id-type="pmid">29727718</pub-id></element-citation></ref><ref id="B61-antibodies-09-00021"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>H.</given-names></name><name><surname>Ma</surname><given-names>Z.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name></person-group><article-title>A novel intracellularly expressed NS5B-specific nanobody suppresses bovine viral diarrhea virus replication</article-title><source>Vet. Microbiol.</source><year>2019</year><volume>240</volume><fpage>108449</fpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2019.108449</pub-id><pub-id pub-id-type="pmid">31836380</pub-id></element-citation></ref><ref id="B62-antibodies-09-00021"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T.</given-names></name><name><surname>Huang</surname><given-names>M.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Ding</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Sheng</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>C.</given-names></name></person-group><article-title>Selection and characterization of specific nanobody against bovine virus diarrhea virus (BVDV) E2 protein</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0178469</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0178469</pub-id><pub-id pub-id-type="pmid">28582444</pub-id></element-citation></ref><ref id="B63-antibodies-09-00021"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>Construction and characterization of porcine single-chain fragment variable antibodies that neutralize transmissible gastroenteritis virus in vitro</article-title><source>Arch. Virol.</source><year>2019</year><volume>164</volume><fpage>983</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1007/s00705-019-04156-6</pub-id><?supplied-pmid 30729994?><pub-id pub-id-type="pmid">30729994</pub-id></element-citation></ref><ref id="B64-antibodies-09-00021"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Duan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Xiao</surname><given-names>S.</given-names></name><name><surname>Zhou</surname><given-names>E.M.</given-names></name></person-group><article-title>Intracellularly expressed nanobodies against non-structural protein 4 of porcine reproductive and respiratory syndrome virus inhibit virus replication</article-title><source>Biotechnol. Lett.</source><year>2016</year><volume>38</volume><fpage>1081</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1007/s10529-016-2086-3</pub-id><?supplied-pmid 27010387?><pub-id pub-id-type="pmid">27010387</pub-id></element-citation></ref><ref id="B65-antibodies-09-00021"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Duan</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>A.</given-names></name><name><surname>Liang</surname><given-names>C.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Li</surname><given-names>N.</given-names></name><etal/></person-group><article-title>An intracellularly expressed Nsp9-specific nanobody in MARC-145 cells inhibits porcine reproductive and respiratory syndrome virus replication</article-title><source>Vet. Microbiol.</source><year>2015</year><volume>181</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2015.10.021</pub-id><?supplied-pmid 26525739?><pub-id pub-id-type="pmid">26525739</pub-id></element-citation></ref><ref id="B66-antibodies-09-00021"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boruah</surname><given-names>B.M.</given-names></name><name><surname>Liu</surname><given-names>D.</given-names></name><name><surname>Ye</surname><given-names>D.</given-names></name><name><surname>Gu</surname><given-names>T.-j.</given-names></name><name><surname>Jiang</surname><given-names>C.-l.</given-names></name><name><surname>Qu</surname><given-names>M.</given-names></name><name><surname>Wright</surname><given-names>E.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>He</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Single Domain Antibody Multimers Confer Protection against Rabies Infection</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e71383</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0071383</pub-id><pub-id pub-id-type="pmid">23977032</pub-id></element-citation></ref><ref id="B67-antibodies-09-00021"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molinkov&#x000e1;</surname><given-names>D.</given-names></name><name><surname>Skl&#x000e1;dal</surname><given-names>P.</given-names></name><name><surname>Celer</surname><given-names>V.</given-names></name></person-group><article-title>In vitro neutralization of equid herpesvirus 1 mediated by recombinant antibodies</article-title><source>J. Immunol. Methods</source><year>2008</year><volume>333</volume><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2008.01.019</pub-id><pub-id pub-id-type="pmid">18329664</pub-id></element-citation></ref><ref id="B68-antibodies-09-00021"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmsen</surname><given-names>M.M.</given-names></name><name><surname>van Solt</surname><given-names>C.B.</given-names></name><name><surname>Fijten</surname><given-names>H.P.D.</given-names></name><name><surname>van Keulen</surname><given-names>L.</given-names></name><name><surname>Rosalia</surname><given-names>R.A.</given-names></name><name><surname>Weerdmeester</surname><given-names>K.</given-names></name><name><surname>Cornelissen</surname><given-names>A.H.M.</given-names></name><name><surname>De Bruin</surname><given-names>M.G.M.</given-names></name><name><surname>Ebl&#x000e9;</surname><given-names>P.L.</given-names></name><name><surname>Dekker</surname><given-names>A.</given-names></name></person-group><article-title>Passive immunization of guinea pigs with llama single-domain antibody fragments against foot-and-mouth disease</article-title><source>Vet. Microbiol.</source><year>2007</year><volume>120</volume><fpage>193</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2006.10.029</pub-id><pub-id pub-id-type="pmid">17127019</pub-id></element-citation></ref><ref id="B69-antibodies-09-00021"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmsen</surname><given-names>M.M.</given-names></name><name><surname>Fijten</surname><given-names>H.P.D.</given-names></name><name><surname>Engel</surname><given-names>B.</given-names></name><name><surname>Dekker</surname><given-names>A.</given-names></name><name><surname>Ebl&#x000e9;</surname><given-names>P.L.</given-names></name></person-group><article-title>Passive immunization with llama single-domain antibody fragments reduces foot-and-mouth disease transmission between pigs</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>1904</fpage><lpage>1911</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.01.110</pub-id><pub-id pub-id-type="pmid">19368770</pub-id></element-citation></ref><ref id="B70-antibodies-09-00021"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name></person-group><article-title>Single chain fragment variable (scFv) antibodies targeting the spike protein of porcine epidemic diarrhea virus provide protection against viral infection in piglets</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>58</elocation-id><pub-id pub-id-type="doi">10.3390/v11010058</pub-id></element-citation></ref><ref id="B71-antibodies-09-00021"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffiths</surname><given-names>A.D.</given-names></name><name><surname>Williams</surname><given-names>S.C.</given-names></name><name><surname>Hartley</surname><given-names>O.</given-names></name><name><surname>Tomlinson</surname><given-names>I.M.</given-names></name><name><surname>Waterhouse</surname><given-names>P.</given-names></name><name><surname>Crosby</surname><given-names>W.L.</given-names></name><name><surname>Kontermann</surname><given-names>R.E.</given-names></name><name><surname>Jones</surname><given-names>P.T.</given-names></name><name><surname>Low</surname><given-names>N.M.</given-names></name><name><surname>Allison</surname><given-names>T.J.</given-names></name></person-group><article-title>Isolation of high affinity human antibodies directly from large synthetic repertoires</article-title><source>EMBO J.</source><year>1994</year><volume>13</volume><fpage>3245</fpage><lpage>3260</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1994.tb06626.x</pub-id><pub-id pub-id-type="pmid">8045255</pub-id></element-citation></ref><ref id="B72-antibodies-09-00021"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S.</given-names></name><name><surname>Aresu</surname><given-names>L.</given-names></name><name><surname>Comazzi</surname><given-names>S.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Worrall</surname><given-names>E.</given-names></name><name><surname>Clayton</surname><given-names>J.</given-names></name><name><surname>Humphries</surname><given-names>W.</given-names></name><name><surname>Hemmington</surname><given-names>S.</given-names></name><name><surname>Davis</surname><given-names>P.</given-names></name><name><surname>Murray</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine</article-title><source>PLoS ONE</source><year>2016</year><volume>11</volume><elocation-id>e0148366</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0148366</pub-id><pub-id pub-id-type="pmid">26894679</pub-id></element-citation></ref><ref id="B73-antibodies-09-00021"><label>73.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Ecker</surname><given-names>D.M.</given-names></name><name><surname>Jones</surname><given-names>S.D.</given-names></name><name><surname>Levine</surname><given-names>H.L.</given-names></name></person-group><article-title>The therapeutic monoclonal antibody market</article-title><source>MAbs</source><publisher-name>Taylor &#x00026; Francis</publisher-name><publisher-loc>Milton Park, Milton, UK</publisher-loc><publisher-loc>Abingdon, UK</publisher-loc><year>2015</year></element-citation></ref><ref id="B74-antibodies-09-00021"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deal</surname><given-names>C.E.</given-names></name><name><surname>Balazs</surname><given-names>A.B.</given-names></name></person-group><article-title>Vectored antibody gene delivery for the prevention or treatment of HIV infection</article-title><source>Curr. Opin. HIV AIDS</source><year>2015</year><volume>10</volume><fpage>190</fpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000145</pub-id><?supplied-pmid 25700206?><pub-id pub-id-type="pmid">25700206</pub-id></element-citation></ref><ref id="B75-antibodies-09-00021"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strohl</surname><given-names>W.R.</given-names></name></person-group><article-title>Current progress in innovative engineered antibodies</article-title><source>Protein Cell</source><year>2018</year><volume>9</volume><fpage>86</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1007/s13238-017-0457-8</pub-id><?supplied-pmid 28822103?><pub-id pub-id-type="pmid">28822103</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="antibodies-09-00021-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(<bold>A</bold>) Structure of a conventional antibody and its derivatives. Abbreviations: Fv, fragment variable; Fc, fragment crystallizable; Fab, fragment antigen binding; scFv, single-chain variable fragment with linker (yellow); scFab, single-chain Fab; VH, variable domain heavy chain; F(ab)2, two Fab fragments joined together; scFv&#x02013;Fc, scFv linked to Fc (inter- and intra-disulfide linkages are not shown here in the all formats). (<bold>B</bold>) Camelid heavy chain antibody (HCAb); VHH, nanobody (modified from [<xref rid="B3-antibodies-09-00021" ref-type="bibr">3</xref>]).</p></caption><graphic xlink:href="antibodies-09-00021-g001"/></fig><fig id="antibodies-09-00021-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Synthesis and cloning of scFv and Fab fragments in a phagemid vector. It starts with the preparation of peripheral blood mononuclear cells (PBMCs) using density gradient from whole blood. Following RNA extraction from PBMCs, cDNA is synthesized through reverse transcription. From cDNA, the variable region of heavy (VH) and light chain (VL) is amplified through PCR using specific primers. scFv and Fab are constructed through splicing by overlap extension PCR(SOE-PCR). The amplified scFv and Fab are ligated into the phagemid vector following restriction digestion of both.</p></caption><graphic xlink:href="antibodies-09-00021-g002"/></fig><fig id="antibodies-09-00021-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Schematic diagram of M13 phage. It carries ~6.4-kb sized circular single-stranded DNA (ssDNA), which encodes for 10 proteins, i.e., p I, p II, p III, p IV, p V, p VI, p VII, p VIII, p IX, and p X.</p></caption><graphic xlink:href="antibodies-09-00021-g003"/></fig><fig id="antibodies-09-00021-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Panning of an antibody phage display library for the generation of high-affinity antibodies. The antigen is presented in its native form either immobilized on a plastic surface or expressed on the cell surface. For membrane protein targets, nanodisc provides a membrane-like environment. Antibody library displaying phages are incubated with antigen, and non-bound or weakly bound phages are removed by washing. The tightly bound phages are recovered by elution via trypsin or pH shift for the re-infection of <italic>E. coli</italic> cells. Following the coinfection with helper phages, new phage particles are produced for usage in subsequent rounds of panning. This cycle continues for 3&#x02013;4 rounds, leading to enrichment of binders.</p></caption><graphic xlink:href="antibodies-09-00021-g004"/></fig><table-wrap id="antibodies-09-00021-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">antibodies-09-00021-t001_Table 1</object-id><label>Table 1</label><caption><p>Summary of the phage display derived antibodies with their potential use in veterinary medicine.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Application of Antibody</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Antibody Format</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Source Species</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Target</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="21" align="center" valign="middle" colspan="1">Diagnosis</td><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">Recombinant NP protein of avian influenza virus in poultry</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B35-antibodies-09-00021" ref-type="bibr">35</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">NP protein of AIV in poultry</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B36-antibodies-09-00021" ref-type="bibr">36</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Rabbit</td><td align="left" valign="middle" rowspan="1" colspan="1">F2 protein of Newcastle disease virus in poultry</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B37-antibodies-09-00021" ref-type="bibr">37</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Chicken</td><td align="left" valign="middle" rowspan="1" colspan="1">Phosphoprotein of Newcastle disease virus in poultry</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B38-antibodies-09-00021" ref-type="bibr">38</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Chicken</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole infectious bursal disease virus in poultry</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B39-antibodies-09-00021" ref-type="bibr">39</xref>,<xref rid="B40-antibodies-09-00021" ref-type="bibr">40</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">VP1 protein of duck hepatitis A virus-1 in ducks</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B41-antibodies-09-00021" ref-type="bibr">41</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">Foot and mouth disease virus type O in cows</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B42-antibodies-09-00021" ref-type="bibr">42</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Chicken</td><td align="left" valign="middle" rowspan="1" colspan="1">3ABC protein of foot and mouth disease virus in cows</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B43-antibodies-09-00021" ref-type="bibr">43</xref>,<xref rid="B44-antibodies-09-00021" ref-type="bibr">44</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">VP2 of protein of foot and mouth disease virus in cows</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B45-antibodies-09-00021" ref-type="bibr">45</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">Capsid protein of bovine immunodeficiency virus in cows</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B46-antibodies-09-00021" ref-type="bibr">46</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">Capsid protein of porcine circovirus type in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B47-antibodies-09-00021" ref-type="bibr">47</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">Membrane proteins of porcine epidemic diarrhea virus in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B48-antibodies-09-00021" ref-type="bibr">48</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">E2 protein of classical swine fever virus in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B49-antibodies-09-00021" ref-type="bibr">49</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">P protein of, swine influenza virus in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B50-antibodies-09-00021" ref-type="bibr">50</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">N protein and spike protein of porcine epidemic diarrhea virus</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B51-antibodies-09-00021" ref-type="bibr">51</xref>,<xref rid="B52-antibodies-09-00021" ref-type="bibr">52</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Dog</td><td align="left" valign="middle" rowspan="1" colspan="1">Capsid protein of canine parvovirus in dogs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B53-antibodies-09-00021" ref-type="bibr">53</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole Western equine encephalitis virus</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B54-antibodies-09-00021" ref-type="bibr">54</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole Venezuelan equine encephalitis virus</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B55-antibodies-09-00021" ref-type="bibr">55</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Human *</td><td align="left" valign="middle" rowspan="1" colspan="1">transmembrane envelope glycoprotein gp46 of Maedi-visna virus in sheep</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B21-antibodies-09-00021" ref-type="bibr">21</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Human *</td><td align="left" valign="middle" rowspan="1" colspan="1">P25 of Maedi-visna virus in sheep</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B56-antibodies-09-00021" ref-type="bibr">56</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Chicken</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole blue-tongue virus in sheep</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B57-antibodies-09-00021" ref-type="bibr">57</xref>]</td></tr><tr><td rowspan="10" align="center" valign="middle" style="border-top:solid thin" colspan="1">Therapy</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">HA antigen of H5N1 in poultry</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B58-antibodies-09-00021" ref-type="bibr">58</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Fab</td><td align="center" valign="middle" rowspan="1" colspan="1">Chicken</td><td align="left" valign="middle" rowspan="1" colspan="1">HA0 hemagglutinin of H5N1 in poultry</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B59-antibodies-09-00021" ref-type="bibr">59</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Mouse</td><td align="left" valign="middle" rowspan="1" colspan="1">VP3 protein duck hepatitis A virus-1 in ducks</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B60-antibodies-09-00021" ref-type="bibr">60</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">NS5B protein of bovine viral diarrhea virus in cows</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B61-antibodies-09-00021" ref-type="bibr">61</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">E2 protein bovine viral diarrhea virus in cows</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B62-antibodies-09-00021" ref-type="bibr">62</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Pig</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole transmissible gastroenteritis virus in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B63-antibodies-09-00021" ref-type="bibr">63</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">non-structural protein 4 of porcine reproductive and respiratory syndrome virus in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B64-antibodies-09-00021" ref-type="bibr">64</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">non-structural protein 9 of porcine reproductive and respiratory syndrome virus in pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B65-antibodies-09-00021" ref-type="bibr">65</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole rabies virus in dogs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B66-antibodies-09-00021" ref-type="bibr">66</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" rowspan="1" colspan="1">Human *</td><td align="left" valign="middle" rowspan="1" colspan="1">gD protein of equid herpesvirus-1 in horses</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B67-antibodies-09-00021" ref-type="bibr">67</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin;border-top:solid thin" colspan="1">Immunoprophylaxis</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Whole food and mouth virus type O in cows</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B68-antibodies-09-00021" ref-type="bibr">68</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">VHH</td><td align="center" valign="middle" rowspan="1" colspan="1">Camelid</td><td align="left" valign="middle" rowspan="1" colspan="1">Whole food and mouth virus in cows pigs</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B69-antibodies-09-00021" ref-type="bibr">69</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">scFv</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pig</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Spike protein of porcine epidemic diarrhea virus in pigs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-antibodies-09-00021" ref-type="bibr">70</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>* Synthetic human Griffin.1 [<xref rid="B71-antibodies-09-00021" ref-type="bibr">71</xref>].</p></fn></table-wrap-foot></table-wrap></floats-group></article>